Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Durable Response in Adolescent Patients With Moderate-toSevere Atopic Dermatitis
SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · s834
DOI: 10.25251/31rhrb86 ↗Abstract
Introduction: In the maintenance periods of ADvocate1 and ADvocate2, efficacy was consistent between the every 2 weeks and every 4 weeks (Q4W) maintenance dosing regimens, and a high proportion of Week 16 responders in the lebrikizumab withdrawal arm exhibited durable efficacy, suggesting less frequent dosing could maintain effectiveness in atopic dermatitis (AD). An extension to the ADjoin long-term study (ADjoin extension) subsequently evaluated the Q8W interval as a maintenance regimen. In the overall ADjoin extension population, Q8W has been reported to provide clinical responses consistent with Q4W dosing. As approximately 10% of adolescents have AD, this analysis describes whether adolescents in the ADjoin extension had a durable response over 32 weeks of Q4W or Q8W dosing. Methods: ADjoin extension was a 32-week study that enrolled patients with AD who had completed the 100-week long-term ADjoin study (NCT04392154) after participation in the parent studies. Key eligibility criteria included being adults or adolescents (≥12–
EUVIMED